1月6日，A股三大股指早盘继续走高，沪指刷新2015年7月底以来的新高，创业板一度站上3300点，脑机接口、半导 体设备等板块继续活跃。港股同样上涨，恒指、恒科指双双涨超1%，科网股悉数拉升，京东健康涨超7%。债市方 面，国债期货全线下跌。商品方面，国内商品期货涨跌不一，金属期货继续走高，其中铂金、钯金、沪银、沪铜悉 数拉升，焦煤、焦炭下跌。核心市场走势： | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | | 4058.69 | 35.27 | 0.88% | | 399001 | 深证成指 | | 13903.77 | 75.14 | 0.54% | | 399006 | 创业板指 | 14.1 | 3284.35 | -10.21 | -0.31% | | 000300 | 沪深300 | | 4759.76 | 42.01 | 0.89% | | 000016 | FiFFSO | | 3146.57 | 46.82 | 1.51% | | 000680 | 科创综 | | ...

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].

2026年首个交易日，A股市场取得"开门红"，上证指数延续强势走出12连阳罕见走势，一举突破并站稳4000点整数关口，为全年行情奠定坚实基础。 沪指重上4000点 指数表现方面，三大股指全天高开高走，震荡上行。截至收盘，上证指数报4023.42点，上涨1.38%，涨幅54.58点，成功重返4000点上方，日线12连阳的走 势创下近期市场强势纪录；深证成指表现更为强劲，收于13828.63点，大涨2.24%，涨幅303.61点，突破阶段新高；创业板指涨幅领先，收报3294.55点，大 涨2.85%，尽显成长股活力。全市场呈现普涨格局，沪深京三市超4100只个股飘红，3959只个股实现上涨，126只个股强势涨停，仅1111只个股下跌。 从板块表现来看，热点赛道全面开花，主线特征鲜明。脑机接口概念成为今日最耀眼的明星板块，受益于马斯克旗下神经连接公司2026年大规模量产脑机接 口设备的消息催化，三博脑科、创新医疗等20余只相关个股集体封板，板块内近40股涨幅超10%；半导体产业链同步走强；存储芯片方向凭借美股相关板块 大涨的联动效应及国产替代逻辑，香农芯创、江波龙等个股强势拉升，中芯国际涨近5%，进一步夯实科技主线 ...

Market Performance - The Shanghai Composite Index reached a new high since July 2015, with a peak of 4048.90, reflecting a 0.63% increase [1][6][7] - The trading volume was significant, with a total turnover of 237 billion, and 1516 stocks rising while 712 fell [2][7] Solid-State Battery Sector - The solid-state battery concept saw a surge, with stocks like Puli Tech and Jinlongyu hitting the daily limit, and companies such as Aotewi and Dao's Technology rising over 10% [2][3][8] - Donut Lab announced the launch of the world's first commercially viable solid-state battery at the CES 2026, emphasizing its readiness for production [3][8] - CICC predicts that solid-state batteries will achieve technical stabilization and small-scale production by 2027, with commercial production expected by 2030, and demand potentially exceeding 150 GWh [4][9] Investment Recommendations - Investment direction suggests focusing on equipment manufacturers capable of complete line delivery and those benefiting from process marginal changes as the solid-state battery industry approaches commercialization [4][9] - The brain-computer interface sector continues to show strength, with companies like Sanbo Neuroscience experiencing consecutive gains [4][10]

早盘，人脑工程板块表现活跃。板块内11只个股涨停。三博脑科、翔宇医疗、爱朋医疗、美好医疗 20CM涨停，伟思医疗涨超19%，麦澜德、诚益通涨超14%，熵基科技涨超12%，道氏技术、博拓生物 涨超10%，创新医疗、普利特、岩山科技、塞力医疗、盈趣科技、南京熊猫、国际医学涨停。 消息面上，马斯克旗下Neuralink宣布将在2026年启动脑机接口设备大规模生产，同步推进流程高度精 简、几乎完全自动化的手术方案，电极丝可直接穿过硬脑膜无需切除，有效规避传统侵入式设备的创伤 性瓶颈，实现效率与成本的双向优化。 同时，OpenAI首席执行官Sam Altman参与创立的脑机接口初创公司MergeLabs完成分拆独立，将专注于 超声波读取脑部活动技术研发，无需植入电极即可大范围解读大脑信号，为脑机接口应用提供全新技术 路径。 脑机接口核心技术研发：作为人脑工程的核心赛道，掌握信号采集、算法处理等核心技术的企业将率先 受益于行业技术迭代与商业化落地。随着侵入式与非侵入式技术同步推进，具备自主研发能力、拥有技 术壁垒的企业将抢占市场先机，分享行业高速增长红利。 医疗设备制造：脑机接口的商业化应用需要大量定制化医疗设备支持，包 ...

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

Market Performance - Major market indices opened with mixed results, with the Shanghai Composite Index rising by 0.06% to 4026.02 points, and the Shenzhen Component Index increasing by 0.01% to 13830.30 points, while the ChiNext Index fell by 0.45% to 3279.81 points [1] Individual Stock Performance - A total of 1552 stocks rose at the open, with 18 stocks hitting the daily limit up, including Victory Energy with 13 consecutive limit ups, Fenglong Co. with 8 consecutive limit ups, and *ST Dongyi with 7 limit ups in 10 days [1] - Conversely, 1194 stocks declined, with three stocks hitting the daily limit down, including Dengyun Co. and *ST Aowei [1] Price Continuity Statistics - Among the stocks that hit the limit up yesterday, 17 stocks continued to hit the limit up today, including Beiyikang and Sanbo Brain Science [1] - Stocks that opened lower included Xiong Plastic Technology, Kairuide, and Wangzi New Materials, with opening declines of 2.25%, 1.76%, and 1.71% respectively [1] - Stocks that hit the limit down yesterday saw significant opening declines today, with Hainan Development, *ST Aowei, and Evergrande High-tech experiencing opening declines of 9.93%, 5.26%, and 4.24% respectively [1]

北京商报讯（记者 丁宁）1月6日，延续前一交易日大涨走势，人脑工程板块涨幅明显。 具体来看，三博脑科、美好医疗开盘"20cm"涨停，爱朋医疗、翔宇医疗等高开超10%。 ...

每经AI快讯，1月6日早盘，脑机接口概念延续强势，岩山科技（002195）、南京熊猫（600775）、创 新医疗（002173）、倍益康、美好医疗（301363）、三博脑科（301293）封涨停，爱朋医疗 （300753）、熵基科技（301330）、翔宇医疗、伟思医疗等高开超10%。 ...

Core Insights - The announcement by Elon Musk regarding Neuralink's mass production of brain-machine interface (BMI) devices has significantly boosted market confidence in the commercialization of this technology, leading to a surge in related A-share stocks on the first trading day of 2026 [2][3][10] Group 1: Market Reaction - On January 5, 2026, domestic BMI concept stocks collectively opened high, with companies like Beikang rising over 29.98% and several others hitting the daily limit of 20% [1] - The market's positive response reflects high expectations for the commercial prospects of brain-machine interfaces following Musk's announcements [2][3] Group 2: Neuralink's Developments - Neuralink has completed seven rounds of financing, raising over $1.3 billion, which is significant compared to the projected $2.9 billion global market size for BMIs in 2025 [3][4] - The company has achieved several milestones, including FDA approval for human clinical trials and the first human implantation of a BMI, marking its leadership in the field [3][4] Group 3: Clinical Advancements in China - 2025 was termed the "Year of Chinese Brain-Machine Interfaces," with numerous clinical breakthroughs in restoring motor and speech abilities for high-level paraplegics, visual reconstruction, and treatment of mental disorders [7][8][10] - Key clinical trials have been conducted by various institutions, demonstrating significant advancements in BMI technology and its applications [9] Group 4: Regulatory and Market Developments - The introduction of policies such as the inclusion of BMIs in medical insurance and the establishment of regulatory frameworks for BMI medical devices indicate a move towards commercialization [10] - In 2025, the Chinese BMI sector saw 24 financing rounds, a 30% increase year-on-year, signaling growing investor interest and confidence in the market [10] Group 5: Competitive Landscape - Despite the surge in stock prices, there are currently no pure-play BMI companies listed in China, with many firms still in the process of developing their products and seeking IPO opportunities [11][12] - Companies like Qiangnao Technology and Bori Kang are actively pursuing IPOs, indicating a competitive race to become the first publicly listed BMI company in China [12][13] Group 6: Future Outlook - The industry is expected to enter a commercialization phase in 2026, with a competitive landscape emerging as various companies aim to establish themselves in the market [14]